This article is more than 5 years old. Information may no longer be current.

pSivida submits NDA for Durasert

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A new drug application has been submitted to the FDA by pSivida for Durasert, its 3-year treatment for posterior segment uveitis, the company announced.

Two phase 3 trials have shown Durasert to reduce the recurrence of posterior segment uveitis in patients through 6 months of treatment.

“Our goal with Durasert is to provide relief to the thousands of patients suffering from this debilitating disease for which today’s standard of care is frequent injections of steroids or an implant that lasts up to 3 months with much higher costs,” Nancy Lurker, pSivida president and CEO, said in a press release.

The FDA recently waived the $2.4 million NDA fee for Durasert under a small business waiver of the Prescription Drug User Fee Act.